Lexicon Pharmaceuticals, Inc. (LXRX)
2.24
+0.05
(+2.28%)
USD |
NASDAQ |
Sep 02, 10:22
Lexicon Pharmaceuticals Research and Development Expense (Annual) : 60.50M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 60.50M |
| December 31, 2024 | 82.85M |
| December 31, 2023 | 58.33M |
| December 31, 2022 | 52.39M |
| December 31, 2021 | 54.75M |
| December 31, 2020 | 149.39M |
| December 31, 2019 | 90.07M |
| December 31, 2018 | 100.24M |
| December 31, 2017 | 152.22M |
| December 31, 2016 | 178.15M |
| December 31, 2015 | 95.19M |
| December 31, 2014 | 84.38M |
| December 31, 2013 | 89.68M |
| Date | Value |
|---|---|
| December 31, 2012 | 78.38M |
| December 31, 2011 | 91.83M |
| December 31, 2010 | 78.52M |
| December 31, 2009 | 81.24M |
| December 31, 2008 | 108.58M |
| December 31, 2007 | 104.33M |
| December 31, 2006 | 106.70M |
| December 31, 2005 | 93.62M |
| December 31, 2004 | 90.59M |
| December 31, 2003 | |
| December 31, 2002 | |
| December 31, 2001 | 53.36M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Viatris, Inc. | 952.50M |
| Pfizer Inc. | 10.25B |
| ANI Pharmaceuticals, Inc. | 51.66M |
| Corcept Therapeutics, Inc. | 254.91M |
| Veru, Inc. | 15.59M |